RaySearch Laboratories AB (publ)
OTC:RSLBF
RaySearch Laboratories AB (publ)
OTC:RSLBF
Price:
23
USD
Market Cap:
$612.4m
Balance Sheet
Balance Sheet Decomposition
RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ)
Balance Sheet Decomposition is not available for
RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ)
Balance Sheet
RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ)
Currency: SEK
| Dec-2014 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
56
|
88
|
104
|
112
|
114
|
169
|
103
|
160
|
344
|
463
|
407
|
|
| Cash |
0
|
88
|
104
|
112
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
56
|
0
|
0
|
0
|
114
|
169
|
103
|
160
|
344
|
463
|
407
|
|
| Total Receivables |
0
|
334
|
419
|
459
|
423
|
362
|
384
|
398
|
414
|
468
|
541
|
|
| Accounts Receivables |
0
|
330
|
414
|
431
|
386
|
301
|
0
|
371
|
384
|
445
|
474
|
|
| Other Receivables |
0
|
4
|
5
|
28
|
37
|
61
|
0
|
28
|
30
|
23
|
68
|
|
| Inventory |
0
|
0
|
0
|
10
|
5
|
9
|
30
|
14
|
9
|
11
|
22
|
|
| Other Current Assets |
0
|
14
|
21
|
23
|
41
|
38
|
0
|
55
|
36
|
43
|
0
|
|
| Total Current Assets |
0
|
436
|
544
|
604
|
582
|
577
|
516
|
628
|
802
|
985
|
971
|
|
| PP&E Net |
0
|
36
|
36
|
93
|
221
|
187
|
667
|
649
|
590
|
527
|
447
|
|
| PP&E Gross |
0
|
36
|
36
|
93
|
221
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
25
|
37
|
53
|
107
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
243
|
323
|
377
|
428
|
487
|
523
|
519
|
530
|
548
|
559
|
|
| Note Receivable |
0
|
2
|
12
|
23
|
20
|
27
|
10
|
55
|
24
|
28
|
7
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
7
|
12
|
7
|
29
|
26
|
6
|
4
|
8
|
|
| Total Assets |
0
N/A
|
717
N/A
|
915
+28%
|
1 105
+21%
|
1 264
+14%
|
1 285
+2%
|
1 745
+36%
|
1 876
+8%
|
1 953
+4%
|
2 091
+7%
|
1 992
-5%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
12
|
27
|
32
|
33
|
20
|
49
|
24
|
42
|
39
|
35
|
|
| Accrued Liabilities |
0
|
50
|
50
|
61
|
67
|
53
|
0
|
17
|
42
|
57
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
74
|
124
|
85
|
93
|
70
|
58
|
97
|
77
|
78
|
|
| Other Current Liabilities |
0
|
63
|
81
|
119
|
173
|
263
|
398
|
515
|
494
|
531
|
457
|
|
| Total Current Liabilities |
0
|
125
|
232
|
337
|
358
|
428
|
517
|
614
|
675
|
704
|
570
|
|
| Long-Term Debt |
0
|
62
|
10
|
7
|
86
|
54
|
492
|
497
|
432
|
395
|
317
|
|
| Deferred Income Tax |
0
|
71
|
92
|
104
|
115
|
109
|
108
|
107
|
110
|
115
|
119
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Total Liabilities |
0
N/A
|
257
N/A
|
335
+30%
|
448
+34%
|
559
+25%
|
591
+6%
|
1 116
+89%
|
1 219
+9%
|
1 217
0%
|
1 214
0%
|
1 007
-17%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
17
|
17
|
17
|
17
|
17
|
0
|
17
|
17
|
17
|
0
|
|
| Retained Earnings |
0
|
449
|
567
|
646
|
694
|
685
|
0
|
640
|
722
|
857
|
0
|
|
| Additional Paid In Capital |
0
|
2
|
2
|
2
|
2
|
2
|
0
|
2
|
2
|
2
|
0
|
|
| Other Equity |
0
|
8
|
6
|
7
|
8
|
10
|
628
|
2
|
6
|
1
|
985
|
|
| Total Equity |
0
N/A
|
460
N/A
|
580
+26%
|
657
+13%
|
705
+7%
|
694
-2%
|
628
-10%
|
657
+5%
|
735
+12%
|
877
+19%
|
985
+12%
|
|
| Total Liabilities & Equity |
0
N/A
|
717
N/A
|
915
+28%
|
1 105
+21%
|
1 264
+14%
|
1 285
+2%
|
1 745
+36%
|
1 876
+8%
|
1 953
+4%
|
2 091
+7%
|
1 992
-5%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
34
|
34
|
34
|
34
|
34
|
34
|
34
|
34
|
34
|
34
|
|
Switch to:
Switch to:
See Also
Discover More
